8-K
filed September 1, 2023, 7:59 PM ET
CIK 0001113148
leadership
confidence high
sentiment negative
materiality 0.90
INFINITY PHARMACEUTICALS, INC.: restructuring charge — Infinity Pharmaceuticals replaces CEO, CMO, and CSO; restructuring charge of $3.9M
INFINITY PHARMACEUTICALS, INC.
- CEO Adelene Perkins and CMO Dr. Robert Ilaria terminated without cause effective Sept 1, 2023; CSO Stephane Peluso also terminated.
- Seth Tasker (former SVP, Chief Business Officer) appointed CEO effective Sept 1, 2023.
- August restructuring adds 3 positions to earlier 21-headcount reduction; expects $3.9M one-time charge ($1.6M cash) in Q3 2023.
- Perkins and Ilaria signed severance agreements (9 months pay vs 12) and consulting deals to find alternative path for eganelisib after terminated MEI Pharma merger.
- $537,876 severance for Perkins; $356,362 for Ilaria; both also receive retention fees and reduced COBRA payments.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Seth Tasker was appointed as Chief Executive Officer at INFINITY PHARMACEUTICALS, INC..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
On August 29, 2023, the Board approved the appointment, effective as of September 1, 2023, of Seth Tasker, J.D., 45, as Chief Executive Officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Ilaria, Jr. departed as Chief Medical Officer at INFINITY PHARMACEUTICALS, INC..
- Action
- terminated without cause
- Role
- Chief Medical Officer
Exact text from the filing
the Board approved the termination, without cause, of the employment of Adelene Perkins as Chief Executive Officer of the Company, and Robert Ilaria, Jr., M.D., as Chief Medical Officer of the Company, effective September 1, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Adelene Perkins changed role as Chief Executive Officer at INFINITY PHARMACEUTICALS, INC..
- Action
- terminated without cause
- Role
- Chief Executive Officer
Exact text from the filing
the Board approved the termination, without cause, of the employment of Adelene Perkins as Chief Executive Officer of the Company, and Robert Ilaria, Jr., M.D., as Chief Medical Officer of the Company, effective September 1, 2023.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
INFINITY PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.9 million (reduction of 3 positions).
- Type
- restructuring
- Charge
- approximately $3.9 million
- Headcount
- reduction of 3 positions
Exact text from the filing
Restructuring is expected to be completed by the end of the third quarter of 2023. The Company expects to incur a one-time charge in the third quarter of 2023 of approximately $3.9 million in severance and restructuring costs in connection with the August Restructuring, of which approximately $1.6 million will represent cash costs. This charge primarily relates to
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.